INTRODUCTION
The gut microbiota is rapidly generating interest worldwide as a result of the increasing awareness that its composition is closely associated with the development and progression of a variety of disorders. In addition, dysbiosis of the gut microbiota, ie, a disturbance or imbalance in the microbial composition and diversity, has been reported to be associated with the pathogenesis of gastrointestinal disorders. 1 Therefore, the question arises whether the gut microbiota plays a role in the etiology, onset, and maintenance of various colonic diseases, such as inflammatory bowel disease or colon cancer. Moreover, it is important to determine whether the microbiota plays a role in mucosal healing, a process essential for maintaining colonic health.
One of the major functions of the gut microbiota is the fermentation of undigested food components into short-chain fatty acids (SCFAs), primarily acetate, propionate, and butyrate. Dietary fibers are the most potent substrates for generating SCFAs. 2 The rate, amount, and type of SCFAs produced are determined by several factors, including the substrate source, the colonic pH, the abundance and composition of gut microbes, and the gut transit time. 3 Depending on these factors, SCFAs can contribute up to 10% of the total human caloric requirement.
subsequently taken up by the colon, playing a pivotal role in colonic health. [5] [6] [7] Of the three main SCFAs, butyrate is considered most important for maintenance of colonic health, primarily by acting as a direct source of energy for colonocytes. Butyrate is almost completely metabolized by colonocytes and is therefore found only in small amounts in peripheral blood. 3 Acetate and propionate also have roles, although smaller, in maintaining colonic health. Most of the acetate, which is formed in higher quantities than the other SCFAs, is rapidly absorbed in the proximal colon and transported to the liver, where it can be used as a substrate for cholesterol synthesis. 3 A recent study showed that less than 1% of the acetate administered colonically was incorporated into cholesterol and less than 15 % into fatty acids. 8 About 90% of the propionate produced is transported to the liver, where it functions as a substrate for gluconeogenesis, lipogenesis, and protein synthesis. 3 Importantly, SCFAs act not only as single components but also influence each other's production and function. 9 In addition, there is a high rate of conversion between the three SCFAs, especially from acetate into butyrate. 8, 10 Currently, there is increasing interest in the therapeutic application of SCFAs in colonic diseases. Several in vitro, ex vivo, and animal studies show positive effects of SCFAs in reducing colonic inflammation, preventing carcinogenesis, and promoting anastomotic healing of the gut. It is unknown, however, whether these results can be translated into clinical practice. This review summarizes the effects of SCFAs reported in in vitro studies and animal studies and links the findings to human clinical trials conducted thus far.
PHYSIOLOGY SCFAs in the colon and in the systemic circulation
Short-chain fatty acids are produced predominantly in the cecum and in the proximal part of the colon, where most substrates are available for bacterial fermentation. These substrates become increasingly depleted along the colon toward the distal part, resulting in decreasing SCFA production. In individuals who died suddenly, total SCFA concentrations were found to be 131 mM in the cecum and 80 mM in the descending colon. 11 However, in individuals who consume a high-fiber diet, concentrations in the proximal colon can reach up to 226 mM acetate, 104 mM propionate, and 78 mM butyrate. 12, 13 The ratio of acetate, butyrate, and propionate throughout the colon is 3:1:1, and it is similar in both the proximal and the distal colon, reflecting a similar uptake of all three SCFAs along the large bowel. 11, 14 The absorption of SCFAs is a quick, efficient, concentration-dependent process, and only 5% to 10% of the total amount of SCFAs present in the proximal large bowel are excreted in the feces. 2 It is important to note that fecal concentrations of SFCAs do not reflect intracolonic concentrations or rates of SCFA production but are a net result of rates of SCFA production and intestinal absorption; hence, these concentrations should be interpreted with care. 15 Short-chain fatty acids that have not been metabolized by colonocytes reach the liver via the portal vein. In addition, some of the SCFAs in the rectum may bypass the liver, as the venous drainage of the rectum occurs partly via the internal iliac vein, directly into the systemic circulation. Since butyrate serves as an important energy source for colonocytes, only a small amount of butyrate reaches the hepatic system and is found in the systemic circulation under physiological conditions. 8 A study in humans undergoing major abdominal surgery showed that the liver is capable of metabolizing large amounts of butyrate administered via an enema, thereby preventing splanchnic release of butyrate and a subsequent increase in systemic butyrate levels. 16 Propionate and acetate released by the gut are processed by the liver. Acetate is the only SCFA that, under normal circumstances, can be found in considerable amounts in peripheral blood in humans. 8, 9, 17 Transport and signaling of SCFAs in the gut Short-chain fatty acids are taken up in the colon via various transport systems. Apical uptake occurs through simple passive diffusion, 18 but the largest part of SCFAs is taken up via several active transport mechanisms: exchange of SCFAs with HCO À 3 ; H þ -dependent cotransport via monocarboxylate transporter (MCT) isoform 1 (MCT1) (SLC16A1); and coupling of SCFAs with sodium ions via sodium-coupled monocarboxylate transporter (SMCT) isoform 1 (SMCT1) (SLC5A8). [19] [20] [21] Normal functioning of these transporters is critical for optimal utilization of SCFAs by colonocytes. The fraction of total SCFAs that is not metabolized by the colonocytes is transported over the basolateral membrane to reach the systemic circulation via HCO À 3 exchange 22 or cotransport via other MCT isoforms, namely MCT4 (SLC16A3) and MCT5 (SLC16A4). 23 In addition to being taken up and metabolized by colonocytes, SCFAs bind to different colonic receptors to act as signaling molecules. 7 In 2003, two G-coupled protein receptors (GPRs) for SCFAs were discovered, namely GPR41 and GPR43 (FFA3 and FFA2 receptors, respectively). 24, 25 Later, Tazoe et al 26, 27 showed that these receptors are expressed in colonic mucosa.
The relative potencies of the different SCFAs to interact with GPR43 are similar, but, for the GPR41 receptor, propionate is more potent than butyrate and is far more potent than acetate. 24 Both receptors are expressed primarily by the enteroendocrine L cells in the intestine, but they are also expressed by mast cells and leukocytes and thereby play an important role in the inflammatory response of the gut. After binding of SCFAs to GPR41 and GPR43, downstream signaling pathways such as mitogen-activated protein kinase signaling (MAPK) are activated, leading to, for example, the production of chemokines and cytokines and the regulation of cell proliferation. 25, 28 More recently, another GPR for butyrate, GPR109a, was discovered. This receptor is expressed in the apical membrane of both colonocytes and enterocytes as well as on colonic immune cells.
29 GPR109a regulates inflammatory processes by suppressing the expression of nuclear factor jB (NF-jB) 29 and promoting the differentiation of colonic regulatory T (T reg ) cells. 30 
MECHANISMS OF ACTION OF SCFAS AT THE CELLULAR LEVEL
The complex effects of SCFAs in colonic health and disease are ascribed to different mechanisms ( Figure 1 ). Short-chain fatty acids have already been shown to provide energy to colonocytes and bind to GPRs to activate downstream signaling pathways. They also inhibit histone deacetylases (HDACs) in colonocytes and mucosal immune cells. Histone deacetylases are enzymes that prevent DNA transcription and thereby regulate gene expression. Studies in colon cancer cells have shown that butyrate is the most potent HDAC inhibitor. Propionate has a moderate effect on HDAC inhibition in the colon, but acetate has no effect. 31 The following section describes several mechanisms through which SCFAs affect colonic health and disease.
Metabolic homeostasis and protection of the colon
In a healthy colon, it is important that colonocytes are protected from external harm so they can grow and proliferate in a normal manner, and preserve metabolic homeostasis. After colonic surgery, an optimal colonic environment is essential for re-epithelialization and mucosal healing.
There are several ways that SCFAs protect colonocytes and maintain colonic homeostasis. Once absorbed, SCFAs, especially butyrate, become an important energy source for colonocytes, allowing them to grow and proliferate. [32] [33] [34] In fact, oxidation of butyrate accounted for more than 70% of the oxygen consumption in colon biopsy specimens, indicating that colonocytes rely more on butyrate oxidation than on glucose as their primary energy source. 35 In addition, in order to increase the metabolic capacity of the colonocytes, SCFAs increase blood flow in the colonic mucosa by exerting a dilatory effect on arteriolar walls and increase oxygen uptake by colonocytes. [36] [37] [38] Several studies have shown that SCFAs activate 5' adenosine monophosphate (AMP) kinase, a key player in the regulation of energy metabolism. Activation of AMP kinase in human colonocytes leads to tightjunction assembly and, thus, a stronger and healthier intestinal barrier. [39] [40] [41] Indeed, several in vitro 42 and ex vivo 43 studies have indicated an improved colonic barrier function after SCFA supplementation. 44 In addition, the administration of SCFAs results in increased cell membrane assembly and mucosal cell migration and enhanced proliferation and differentiation of healthy colonocytes. [45] [46] [47] [48] [49] A healthy intestinal barrier not only enhances mucosal healing but also reduces the chance of colonization and infection by gut bacteria. 50 Importantly, the intestinal barrier helps maintain colonic health, since a strong barrier decreases the possibility of tumor invasion, cell migration, formation of metastases, and inflammation. [51] [52] [53] Not only can SCFAs help rebuild the colonic epithelium, they can also protect it from external harm, such as caused by bacteria, reactive oxygen species, or immune-modulating prostaglandins. To protect the epithelial cells, the mucosa of the gastrointestinal tract is covered by a mucus layer that contains immune cells and protects the underlying epithelium against potentially harmful compounds. Mucus consists of different mucins, of which epithelial mucin 2 (MUC2), encoded by the MUC2 gene, is the most prominent in both the healthy and the inflamed gut. [54] [55] [56] In vitro studies showed that HDAC inhibition via SCFA supplementation enhanced MUC2 expression in intestinal epithelial cells, 54, [57] [58] [59] and exposure of human colonic tissue to butyrate increased mucus synthesis. 60 Administration of SCFAs increases not only MUC2 expression but also the expression of other mucins, such as MUC1, MUC3, and MUC4. 61, 62 Besides the physical barrier of mucus that protects the epithelium, SCFAs can also protect the epithelium by modulating oxidative stress and immune modulators. Evidence that SCFAs can modulate oxidative stress, possibly via HDAC inhibition, is accumulating. 63 Oxidative stress is defined as an imbalance between reactive oxygen species and antioxidant compounds in the body. Reactive oxygen species can be scavenged by antioxidants, such as vitamins, glutathione, uric acid, and ubiquinol. 64 Importantly, a large prospective human study showed that higher serum levels of reactive oxygen species are associated with an increased risk of developing colorectal cancer. 65 Moreover, oxidative stress induces colonic inflammation. [66] [67] [68] In vitro studies showed that butyrate and a physiological mixture of acetate, propionate, and butyrate protects colonocytes from DNA damage induced by reactive oxygen species. 69, 70 In addition, SCFAs protect the mucus layer from injury by reducing levels of immune modulators, such as prostaglandins formed by cyclooxygenase-2 (COX-2). Prostaglandin E2 promotes inflammation and tumor growth in colon cancers, 71 and levels of COX-2 mRNA are higher in colon cancer tissues. 72 In vitro studies show that butyrate is able to suppress COX-2 expression in cancerous tissues, thereby preventing the damaging effects of prostaglandins on the mucus layer. [73] [74] [75] Another important factor in maintenance of the epithelial barrier is hypoxia-inducible factor, a transcription factor that coordinates barrier protection. 43 Loss of epithelial hypoxia-inducible factor has been shown to increase susceptibility to colitis. 44, 76 Interestingly, the addition of butyrate and other SCFAs to cultured epithelial cell lines enhanced local oxygen consumption, thereby stabilizing hypoxia-inducible factor and improving epithelial barrier function. 77 
Colonic inflammation
Short-chain fatty acids have been shown to have direct immune-modulatory effects via HDAC inhibition and GPR activation, as reviewed recently. 44 First, SCFAs inhibit HDACs in colonocytes and mucosal immune cells, thereby regulating gene expression in these cells. 78, 79 Inhibition of HDACs leads to suppression of the nuclear transcription factor NF-jB in several types of cells in the mucosal immune system, thereby influencing transcription of inflammatory-associated genes, including those that code for cytokines. 80, 81 In vivo studies have shown that SCFAs directly modulated Toll-like receptor 4 signaling, suppressed the production of proinflammatory cytokines tumor necrosis factor-a, interleukin (IL)-6, and IL-12, increased the production of the anti-inflammatory cytokine IL-10, and reduced the infiltration of colonic mucosa by leukocytes, thereby directly suppressing the immune response. 82, 83 Recently, SCFAs have also been shown to induce differentiation of mucosal T reg cells via HDAC inhibition. 84, 85 T reg cells expressing transcription factor Foxp3 play an important role in limiting intestinal inflammatory responses via production of IL-10, and in vitro stimulation by SCFAs increased Foxp3 expression by T reg cells. 85 In addition, recent investigation has shown that SCFAs affect immune antibody response through HDAC inhibition. 86 Indeed, in vitro application of SCFAs enhanced the generation of immunoglobulin-expressing B cells. 86 The same study also showed that SCFAs increased acetyl-coenzyme A, and oxidative phosphorylation, glycolysis, and fatty acid synthesis to produce energy needed for antibody production. In practice, increased NF-jB activation was found in colonic biopsies from patients with Crohn's disease. This activation was inhibited by applying butyrate to the specimen and was accompanied by a reduction in the release of several proinflammatory cytokines. 66, 87 Second, SCFAs bind to different GPRs, ie, GPR41, GPR43, and GPR109a, on the apical surface of colonocytes and immune cells, thereby activating several signaling pathways. In particular, GPR43 activation by acetate and propionate, and GPR109a activation by butyrate seem to be important factors in suppressing the inflammatory response. GPR43 activation and, in a less potent manner, GPR41 activation both reduce colonic inflammation. This is achieved by suppressing the expression of adhesion molecules in inflammatory cells and endothelial cells, 88, 89 by preventing chemotaxis of monocytes to the inflammatory site, 90 by promoting chemokine and cytokine production, 28 and by regulating T reg function. 91 Butyrate-induced activation of GPR109a also affects the inflammatory process by suppressing NF-jB 29 expression and promoting the differentiation of T reg cells. 30 
Colon carcinogenesis
Short-chain fatty acids can exert direct anticarcinogenic effects through both HDAC inhibition and GPR activation. Inhibition of HDACs by SCFAs is associated with cell cycle arrest, causing antiproliferative and proapoptotic effects as well as an increase in cell differentiation in colon cancer tissue. 92 A microarray analysis of human colonic epithelial cells showed that most of the genes responsive to butyrate were indeed involved in the processes of apoptosis, proliferation, and differentiation. 93 Butyrate, propionate, and acetate increased apoptosis in several adenoma and carcinoma cells by stimulating the expression of the cell cycle regulatory genes p53 and p21, by decreasing the expression of the antiapoptotic Bcl-2 protein, and by increasing the expression of the proapoptotic Bax protein. 33, 34, 94, 95 Butyrate is the most potent inhibitor of cell proliferation, consistent with it being the most potent HDAC inhibitor, although acetate and propionate seem to augment the effects of butyrate in adenoma cells. 96, 97 Butyrate, propionate, and acetate promoted cell differentiation and inhibited cell migration in colon cancer cells in vitro, thereby reducing the invasiveness of carcinoma cells. [97] [98] [99] [100] [101] In addition, GPR43 and GPR109a both act as tumor suppressors by inhibiting proliferation and increasing apoptosis in colon cancer cell lines, independent of HDAC inhibition. 29, 102 Moreover, butyrate and other HDAC inhibitors inhibit cell growth in colon cancer cell lines, independent of HDAC inhibition, via attenuation of Wnt signaling, a pathway that is active in most colorectal carcinomas and that induces cell proliferation and tumorigenesis in these carcinomas. 103 Some colorectal cancer cells develop so-called butyrate resistance to the apoptotic effects of butyrate, which is related to a different degree of Wnt attenuation. 104 The apparent contradiction in the effects of SCFAs, which provide energy for normal cells to grow and proliferate and yet also inhibit the proliferation of cancer cells, is called the butyrate paradox. 105 It is explained by the Warburg effect: cancerous colonocytes rely on glycolysis for oxidation, even in the presence of SCFAs. Therefore, the accumulating SCFAs inhibit proliferation of cancerous colonocytes, while SCFA oxidation in unaffected cells stimulates proliferation, possibly by affecting different target genes. 106, 107 Another hypothesis proposes that the epithelial architecture, organized in crypts, protects stem cells from growth inhibition, since stem cells are located in the deep base of the crypt, where fewer SCFAs can reach them. 108 In a carcinogenic state, in which the epithelial lining might be disrupted, SCFAs can reach the stem cells and suppress stem cell proliferation.
EVIDENCE FROM ANIMAL STUDIES Inflammation
The important role of SCFAs in inflammation was demonstrated using SCFA-receptor knockout mice and colitis models in animals. Several authors showed beneficial effects of supplementation with SCFAs, mostly butyrate, in experimentally induced colitis.
109-113 GPR43 activation via acetate treatment reduced colitis in mice. 88, 114, 115 In addition, GPR43-deficient mice had a greater inflammatory response to the carcinogen dextran sodium sulfate than their wild-type littermates. The addition of acetate to the drinking water of the GPR43-deficient mice resulted in a substantial decrease in inflammation, showing that acetate could also reduce inflammation by pathways other than GPR43 activation. 89 In an experimental model of diversion colitis in rats, a butyrate enema reduced inflammation, restored collagen, and restored the rate of apoptosis in the epithelium. 116, 117 The butyrate receptor GPR109a protected against the development of colitis and subsequent colon carcinoma in GPR109a knockout mice. 30 Moreover, oral butyrate intake ameliorated colitis in mice by increasing T reg cell differentiation, 84, 118 and a butyrate enema lowered NF-OEB expression in mice with colitis. 112, 113 These findings support the conclusion that the in vitro mechanisms of SCFAs are also applicable to animal studies.
Supplementation with dietary fiber, such as guar gum, potato fiber, enzyme-treated rice fiber, and others, reduced inflammation and resulted in improved barrier integrity and mucosal healing in chemically induced (dextran sodium sulfate or 2,4,6,-trinitrobenzene sulfonic acid) and genetic (IL-10 À/À ) animal models of colitis. [119] [120] [121] [122] [123] [124] In these studies, the beneficial effects of fiber on the intestine were associated with overt increases in luminal and/or fecal SCFA levels. In addition, the reduction of SCFA levels observed in colitis (dextran sodium sulfate model and IL-10 À/À model) could be restored by treatment with dietary fiber. 119, 123 Moreover, feeding dietary fiber (pectin and inulin mixture) to mice resulted in improved host antibody responses and reduced susceptibility to pathogens, which appeared to be, at least in part, mediated by increased levels of SCFAs. 86 In a validated rat model of inflammatory bowel disease, however, beneficial effects of the fibers inulin and fructooligosaccharides on intestinal inflammation were associated with concomitant changes in microbiota profiles, although cecal and fecal levels of SCFAs remained unchanged. 125 Hence, dietary fiber may also improve intestinal homeostasis by generating and/or inhibiting other metabolites or by affecting the gut microbiota.
Carcinogenesis
The direct application of SCFAs to the colon might prevent the development of colon cancer. Some studies have confirmed the anticarcinogenic effects of butyrate in animals, [126] [127] [128] but other studies found no effect of butyrate on colon carcinogenesis. [129] [130] [131] In these latter studies, however, only a low concentration of butyrate was used, which might explain the results observed, possibly indicating that a higher concentration is needed to be effective.
Since the direct application of SCFAs in the colon to protect against colon cancer is not physiological, some authors have investigated the use of prodrugs or dietary fibers combined with SCFAs to protect against colon cancer in animals. Prodrugs are inactive compounds that are metabolized by the body into active SCFAs. The advantage of the use of prodrugs is that they, in contrast to SCFAs, provide a stable and high concentration after rapid absorption at the site of administration, while SCFAs themselves are rapidly metabolized by the colonocytes. An example of a prodrug is tributyrin, an ester composed of glycerol and butyrate. Tributyrin is metabolized by intracellular lipases, releasing therapeutically effective butyrate over time directly into the cell. 132 Recent studies show that tributyrin protects carcinogen-treated rats against the development of colon cancer. 133 In addition, a study with carcinogen-treated mice showed a lower tumor incidence of 43% in tributyrin-fed mice compared with 60% in control mice. 134 Clarke et al 135 showed that carcinogen-treated rats fed a butyrylated starch diet had more apoptosis in the distal colon when compared with rats fed a control diet.
It has been hypothesized that the dietary fibermediated suppression of colon carcinogenesis is attributable to butyrate-producing gut bacteria. In a mechanistic study using an inflammation-associated model of colon carcinogenesis in mice, absence of the SCFA receptor GPR43 (Ffar2 À/À ) resulted in decreased animal survival. Dietary fiber was able to suppress weight loss, diarrhea, and the development of colonic polyps, but only in wild-type mice and not in Ffar2 À/À mice. These data indicate that the GPR43 receptor is crucial for the suppression of inflammation-associated colon carcinogenesis by dietary fiber. 136 Interestingly, another mouse study revealed a role for the butyrate receptor GPR109a in this suppression. 137 In rats exposed to a genotoxic challenge with azoxymethane, intake of butyrylated high-amylose maize starch resulted in higher total SCFAs and higher concentrations of acetate and butyrate in the colon, as well as higher concentrations of total SCFAs, acetate, and butyrate in hepatic portal venous plasma, all in a dose-dependent manner. This intervention increased mucus thickness, decreased DNA single-strand breaks, and increased the rate of apoptosis in a dose-related manner in cells in the distal colon. 138 The effects of dietary fiber are thought to be dependent on both the source of the fiber and the composition of the gut microbiota. To investigate this, Donohoe et al 139 used gnotobiotic mouse models colonized with wild-type or mutant strains of a butyrateproducing bacterium to demonstrate that dietary fiber has a potent tumor-suppressive effect, but in a microbiota-and butyrate-dependent manner.
In conclusion, since the use of SCFA enemas in human interventions might not be feasible, the use of prodrugs or dietary fiber might allow the potent effects of SCFAs to be exploited in the prevention of colon cancer in humans. As noted below, whether dietary fiber protects against colorectal cancer is still controversial. It may be possible, however, to discriminate between individuals who respond to the anticancer effect of fiber and those who do not, on the basis of careful analysis of their microbiome. 139 
Mucosal healing and colonic protection
Van der Sluis et al 140 showed that MUC2-deficient mice spontaneously develop colitis and colon cancer, suggesting that the mucus layer has a critical role in colonic homeostasis and protection from external harm. Administering butyrate enemas to mice for 7 days increased MUC2 gene expression, but a decrease in mucus thickness was described. 61 Ferreira et al 111 showed an improved intestinal barrier after adding either a mixture of SCFAs or butyrate alone to the drinking water of mice in a colitis model.
Rolandelli et al 141 were the first to investigate the effects of SCFAs in mucosal healing after surgery. In their study, an anastomosis of the descending colon was made, and continuous colonic infusion with an SCFA mixture of acetate, propionate, and butyrate was administered. Rats without any colonic infusion and rats with colonic electrolyte infusion were used as controls. In the SCFA-treated group, the occurrence of spontaneous anastomotic dehiscence was considerably less, as was the occurrence of anastomotic suture bursting. Bursting pressure and bowel wall tension were higher in the SCFA-treated group than in either of the other groups, indicating that SCFAs in the anastomosed colon led to a stronger anastomosis and better mucosal healing. 141 Other studies have confirmed these positive findings on colonic mucosal healing in rats. 142, 143 In a surgical model of acute colonic obstruction in rats, bursting pressure and bowel wall tension were higher in the SCFA-treated group, and bursting of the colon was more likely to occur in a nonoperated part of the bowel, indicating that the operated site was actually stronger than the rest of the nonoperated part of the colon. 144 Another study of bowel obstruction in rats showed that intraoperative lavage with a SCFA mixture reduced the size of necrotic ulcers at the suture line and resulted in more rapid healing of the mucosal gap at the anastomosis. 50 Again, other animal studies found positive effects of SCFAs on mucosal healing and prevention of adhesions. 45, [145] [146] [147] [148] [149] [150] 
HUMAN EPIDEMIOLOGICAL STUDIES
Gut microbial dysbiosis might play a role in the onset or treatment of gastrointestinal disease. The consumption of specific carbohydrates influences the composition and function of the human microbiome. 151 Because some bacterial species, such as Bifidobacterium, are more potent in generating SCFAs from complex carbohydrates than others, it can be postulated that a change in the microbial composition of the gut, as occurs, for example, by dietary modification or the use of antibiotics, can change both the use and the production of SCFAs. 152 Therefore, microbial dysbiosis, which occurs in gastrointestinal disease, could lead to a change in the production and/or utilization of SCFAs.
The observation that patients with inflammatory bowel disease have a different fecal SCFA profile than healthy controls 153 and the finding of a lower abundance of butyrate-producing bacteria in ulcerative colitis and Crohn's disease patients [154] [155] [156] clearly demonstrate the relationship between microbial dysbiosis, SCFAs, and inflammatory bowel disease in humans. In addition, the number of butyrate-producing bacteria correlated negatively with disease activity in Crohn's disease patients. 157 Fecal SCFA concentrations were also markedly lower in patients with pouchitis than in patients without pouchitis. [158] [159] [160] [161] [162] In a small group of 11 pouch patients, low fecal butyrate appeared to be indicative of the development of pouchitis within the first year after pouch construction. 158 In 1980, Roediger 35 provided the first evidence that SCFAs might influence gut inflammation in humans by showing that colonocytes from patients with ulcerative colitis had a considerably lower capacity for butyrate oxidation when compared with colonocytes from healthy individuals. Importantly, bacterial butyrate and propionate metabolism was decreased in ileal Crohn's disease. 163 Butyrate oxidation was found to be reduced in active, mild to moderate inflammatory disease in ex vivo studies 53, 164 ; however, there seems to be no defect in butyrate oxidation in quiescent disease. 164, 165 In line with this, a recent study found that the inflammatory process itself induces impaired butyrate oxidation but that the inflammation is not a result of lower colonic butyrate levels. 166 The observation that colonic levels of SCFAs, especially acetate, are lower when ulcerative colitis is active than when in remission supports the hypothesis that the inflammation itself might cause the impaired uptake and utilization of SCFAs, instead of SCFAs being the cause of the impairment. 167, 168 These findings imply that, in humans, the immunomodulatory effects of SCFAs on inflamed colonocytes are more important than the recovery of the metabolic deficiency in the inflamed colonocytes.
A role for SCFAs in the development of colon cancer was recently suggested by the downregulation of SCFA receptors MCT1, SMCT1, GPR43, and GPR109a in human colon cancer tissue. 29 172 stated that the lower intake of dietary fiber in developed countries compared with the intake in developing countries causes a difference in colon cancer prevalence. Several studies showed a lower incidence of colon cancer along with higher fecal levels of SCFAs in native Africans compared with African Americans and Caucasian Americans. [173] [174] [175] [176] In addition, the capacity of the colonic bacteria to ferment carbohydrates and to produce butyrate was found in patients with colon cancer or polyps. [177] [178] [179] This all seems to support the hypothesis that a higher intake of complex carbohydrates leads to higher amounts of colonic SCFAs, thereby decreasing the risk of developing colon cancer. Patients with familial adenomatous polyposis are prone to develop colon cancer, since they have a chromosomal defect that initiates adenomatous changes in the gut. Compared with healthy individuals, patients with familial adenomatous polyposis produce fewer fecal SCFAs. 180 When comparing familial adenomatous polyposis patients with and without colonic polyps, Bradburn et al 180 found that patients with polyps produced stool with larger ratios of acetate to butyrate and acetate to propionate. A higher proportion of acetate and a lower proportion of butyrate were also found in the feces of subjects with colon cancer or polyps compared with subjects without colonic disease. 177, 178 These studies, however, are all associative, and the role of SCFAs in colonic health and disease is best investigated in human intervention trials.
CLINICAL HUMAN INTERVENTION TRIALS: INFLAMMATORY DISEASES
Most clinical studies have been conducted in ulcerative colitis because it affects predominantly the distal part of the colon, which is easy to reach using enemas, and manifests as superficial mucosal inflammation. Ulcerative colitis is different than Crohn's disease, which may affect the entire gastrointestinal tract and causes deep ulcers that extend into all layers of the bowel wall, making treatment difficult. Some studies have investigated SCFA treatment in diversion colitis, radiation proctitis, and pouchitis. These diseases vary in pathophysiology, and thus different underlying mechanisms may be involved in treatment outcome.
Ulcerative colitis
Ulcerative colitis is a chronic inflammatory bowel disease that often manifests with symptoms such as diarrhea and rectal blood loss. It is characterized by episodes of active inflammation and periods of more quiescent disease during which patients can be relatively symptom free. The advantage of SCFA enemas is that they cause no side effects, in contrast to treatment with corticosteroids or mesalazine. Several studies have attempted to investigate the role of SCFA or butyrate enemas in the treatment of patients with ulcerative colitis. The results of early uncontrolled studies seemed promising, [181] [182] [183] [184] 181 showed in 1991 that an enema composed of the SCFAs acetate and propionate resulted in symptom improvement in patients with refractory ulcerative colitis. Moreover, a mixture of the SCFAs acetate, propionate, and butyrate improved symptoms in 9 of 10 patients. In addition, in a single-blinded crossover study, 10 patients with distal ulcerative colitis refractory or intolerant to standard therapy for 8 weeks received 2 weeks of butyrate enemas followed by 2 weeks of placebo with a 2-week washout in between. The butyrate enema had a positive effect on stool frequency, rectal blood loss, and endoscopic and histologic inflammation. 185 One study evaluated the effectiveness of SCFA enemas vs mesalazine or corticosteroid enemas in 45 patients with nonspecific proctosigmoiditis, which is not always indistinguishable from ulcerative colitis. 186 The authors showed that SCFAs are equally effective at treating nonspecific proctosigmoiditis when compared with the other two treatments, but the study lacked a placebo group.
The outcomes of subsequent randomized, doubleblind, placebo-controlled studies, however, were less impressive (Table 1 67, 184, 185, [187] [188] [189] [190] [191] [192] ). Most studies report no significant difference between SCFA application and placebo. 67, 188, 189 The most convincing studies are those performed by Steinhart et al 187 and Breuer et al, 190 who investigated 38 and 91 patients with ulcerative colitis, respectively. Both showed no significant effect of SCFA enemas on endoscopic or histologic scores or on clinical disease activity indexes. Only 2 studies from Vernia et al 192, 193 showed improvement after rectal administration of SCFAs. The first study, conducted in 40 patients with mild to moderate ulcerative colitis, found an improvement in clinical signs, such as intestinal bleeding, urgency, and a patient self-evaluation score. No significant difference between butyrate and placebo was found for histologic or endoscopic scores. 193 The second study investigated whether a combination of mesalazine and butyrate was more effective than mesalazine alone in 51 patients with active, mild to moderate ulcerative colitis refractory to standard therapy for 8 weeks. 192 This study also found significant beneficial effects on clinical signs of active disease, such as on stool frequency, urgency, and the patient self-evaluation score. However, no significant effect on histologic or endoscopic scores was found.
The discrepancy between the studies might be due to a pronounced placebo effect, reported by almost all of the placebo-controlled studies. Most studies also describe the presence of specific responders and nonresponders to treatment, which led Lührs et al 191 to use 
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Oxidative stress NS Abbreviations: NaCl, sodium chloride; NF-jB, nuclear factor-kappa B; NS, nonsignificant; SCFAs, short-chain fatty acids; UC, ulcerative colitis; UCDAI, ulcerative colitis daily activity score.
only a subset of patients who positively reacted to butyrate enemas in another study. 188 It is possible that butyrate enemas improve the efficacy of certain medications, such as mesalazine, even when ingested orally as coated tablets. [192] [193] [194] Fiber supplementation in patients with ulcerative colitis is not widely tested, 195 especially not in relation to changes in fecal SCFA levels. An open-label, randomized, controlled multicenter trial was conducted to investigate the efficacy and safety of fermentable dietary fiber (Plantago ovata seeds) vs mesalazine to maintain remission in patients with inactive ulcerative colitis. There was a significant increase in butyrate concentrations and a trend toward increasing acetate and total SCFA concentrations in feces after 3 months of fiber intake. The results failed to show a difference between the treatments in preventing relapse, suggesting that fermentable fiber might be as effective as mesalazine for maintaining remission. 196 More clinical trials should be conducted on this subject.
Overall, although most studies point toward a positive role of SCFAs or fiber supplementation in the treatment of ulcerative colitis, no convincing evidence in placebo-controlled trials has been found. It appears that SCFA agonism is not a sufficient anti-inflammatory stimulus to resolve inflammatory colitis, since the most promising treatment seems to be a combination of SCFAs and other anti-inflammatory agents, such as mesalazine.
Diversion colitis
Diversion colitis can occur after surgical diversion of the fecal stream and may present, for instance, after a Hartmann procedure with closure of the rectum or sigmoid. In a considerable number of patients, the excluded part of the colon will develop moderate to severe inflammation. It has been assumed that lack of luminal SCFAs causes a metabolic deficiency, contributing to inflammation. 116, 197 The abatement of colitis when the fecal stream is restored supports this assumption. 198 The effects of SCFA treatment in diversion colitis were first studied by Harig et al, 199 who showed clinical and endoscopic improvement in 4 patients after SCFA application in the excluded rectosigmoid. A placebo enema of isotonic saline administered during the regimen did not reduce the inflammation. A beneficial effect of SCFA treatment was also found in 5 children with refractory proctocolitis, 200 9 children with acute diversion proctocolitis, 201 and 4 adult patients. 202 However, when investigated in a placebo-controlled manner, these effects could not be confirmed (Table 2 [203] [204] [205] ). Guillemot et al 203 and Schauber et al 204 investigated the effect of a SCFA mixture vs placebo in 13 and 9 patients, respectively. Neither study detected any difference between treatments in patient self-evaluation, endoscopic score, or histologic score. A recent placebo-controlled study by Luceri et al, 205 however, showed significantly improved endoscopic grading after a high amount of butyrate (600 mmol/L) was administered rectally, with no adverse events. In conclusion, the current literature does not convincingly support the benefit of SCFAs in the treatment of diversion colitis, but recent studies point toward improvement of the disease after SCFA treatment.
Radiation proctitis
Radiation proctitis occurs in about 25% of patients receiving radiation therapy for pelvic cancer. It causes severe and debilitating symptoms such as bleeding, pain, and increased stool frequency. 206 The promising effects of SCFAs in other inflammatory diseases prompted the investigation of the effect of SCFAs in the treatment of radiation proctitis. To date, 7 studies have examined the use of SCFAs in the treatment of radiation proctitis. [207] [208] [209] [210] [211] [212] [213] Only 4 of these are randomized, placebo-controlled studies, the rest being open or pilot studies (Table 3 209-211,213 ). In acute radiation proctitis, an overnight butyrate enema for 3 weeks resulted in marked improvement in clinical markers such as stool consistency, rectal blood discharge, and rectal burning or tenesmus as well as a higher patient self-evaluation score when compared with placebo treatment. 211 Endoscopic scores, graded from 0 (normal mucosal pattern) to 3 (mucosal alterations, spontaneous bleeding), and histologic scores, graded from 0 (normal mucosa) to 3 (severe inflammation/damage), tended to differ between the butyrate group and the placebo group. This study included 20 patients, 10 in the treatment arm and 10 in the placebo arm, which is a rather small number. It was originally designed as a randomized crossover trial, but since a carryover effect from the first study period to the second was high, only results from the first study period were reported.
Chronic radiation proctitis was examined in 2 placebo-controlled studies. The first, by Talley et al, 209 was a randomized crossover trial in which 12 patients with chronic radiation proctitis received butyrate twice daily for 2 weeks. No significant effects on clinical, endoscopic, or histologic scores were found when the treatment arm was compared with the placebo arm. In the second study, by Pinto et al, 210 16 patients with chronic radiation proctitis were randomized to receive either a SCFA mixture or placebo, twice daily for 5 weeks. Patients were monitored for 6 months after the enemas were ceased. When compared with placebo, the butyrate enemas had a direct effect on the hemoglobin level, endoscopic score, and histologic fibrosis after the 5-week treatment. One month after the enemas were ceased, there was still a difference between the butyrate and placebo groups in rectal bleeding and the endoscopic score, but this difference was no longer significant 6 months after the enemas ended.
In the fourth placebo-controlled study, the aim was to prevent proctitis in 166 patients undergoing radiation therapy by providing butyrate enemas during the therapy. 213 The patients were divided into 4 groups: 1 group received a placebo, and the other 3 groups received a gradually increasing dose of butyrate (1 g, 2 g, or 4 g). The authors found no effect of the different amounts of butyrate on the occurrence of proctitis, the duration of proctitis, or the endoscopic scores when comparing butyrate treatment and placebo. They did, however, report that the study might have been underpowered, since the incidence of proctitis was calculated as 60%, while the true incidence was 40%.
Overall, SCFA treatment seems to affect the acute phase of radiation proctitis, possibly by speeding the healing process. However, it might not help prevent the disease or the chronic form of it. The lack of an effect on chronic proctitis might be explained by a different mechanism in acute versus chronic proctitis. Acute proctitis is due mainly to acute mucosal injury and inflammation involving various cellular and cytokine pathways that can be influenced by SCFA treatment. Chronic proctitis involves an underlying chronic process of fibrosis and vascular sclerosis, which is not reversible. 214 
Pouchitis
In patients with severe colitis unresponsive to medical interventions, total colectomy with creation of an ileoanal pouch is considered. This pouch may, over time, show signs of mucosal inflammation, a condition called pouchitis. Only one study has investigated SCFA treatment in the pouch of ulcerative colitis patients. The authors showed that SCFA administration decreased the proliferative activity of the mucosa in patients with a pouch, but no effects on endoscopic appearance of the pouch, histopathologic parameters of inflammation, or daily symptoms were observed. 215 Another study investigated the effects of dietary fiber administration in patients with an ileal pouch-anal anastomosis. This placebo-controlled, randomized, double-blind, crossover study revealed that 3 weeks of inulin ingestion resulted in decreased intestinal mucosal inflammation (at histologic and endoscopic levels) as well as changes in the microbiota, increased fecal butyrate levels, and decreased secondary bile acids. 
Crohn's disease
Crohn's disease is a type of inflammatory bowel disease that may present throughout the whole gastrointestinal tract, extending deep into the bowel wall. This makes treatment with topical agents very difficult. To the best of knowledge, only one non-placebo-controlled study providing SCFAs has been performed in patients with Crohn's disease. 217 In that study, 13 patients with mild to moderate Crohn's disease received butyrate twice daily for 8 weeks via enteric-coated tablets designed to release the butyrate in the terminal ileum and colon. Nine patients responded to treatment, of whom 7 had a complete response and 2 a partial response in disease activity as assessed by the Crohn's Disease Activity Index, a research tool used to quantify the symptoms of patients with Crohn's disease. The endoscopic and histologic scores of the patients improved after treatment, and NF-jB and IL-1b protein levels in mucosal biopsies from the terminal ileum had decreased. These results seem promising, but since a placebo effect cannot be excluded, they need to be confirmed by larger placebocontrolled studies.
CLINICAL HUMAN INTERVENTION TRIALS: COLON CARCINOGENESIS
The role of SCFAs in colon carcinogenesis has not been investigated extensively in human trials. Two studies in ulcerative colitis patients treated with nocturnal enemas containing either butyrate or a mixture of SCFAs showed a 40% reduction of proliferating crypt cells in treated patients compared with those who received placebo, indicating that SCFAs may prevent the development of colon cancer in the inflamed state. 185, 189 In healthy humans, however, it is not feasible to apply SCFAs directly into the colon for several years or decades in order to prevent colorectal cancer. Therefore, the intake of fiber is more logical to investigate in a human intervention study. Beyond that, the use of prodrugs, such as tributyrin, would enable an already developed tumor located anywhere in the colon to be reached, and not only tumors in the distal part, which can be reached using enemas.
Le Leu et al 218 recently investigated whether an increased risk of developing colorectal cancer after intake of red meat could be prevented by adding fiber to the diet. In a randomized controlled study, 10 healthy volunteers received a diet high in red meat for 4 weeks, while 13 healthy volunteers ingested the same diet along with 40 g of butyrylated high-amylose maize starch. The authors showed that intake of red meat increased toxic compounds and rectal epithelial proliferation in rectal biopsies, which was counteracted by the addition of butyrylated starch to the diet. A higher excretion of acetate, propionate, and butyrate in the stool of the starch group was found when compared with baseline values. The results imply that dietary fiber protects the gut against toxic compounds and carcinogenic alterations, possibly via fermentation of fiber into SCFAs. Other studies in healthy volunteers 219, 220 and in colorectal cancer patients 221 have confirmed this anticarcinogenic effect of resistant starch, indicating possible protection through SCFA production.
On the other hand, a large multicenter randomized controlled trial in 714 patients with Lynch syndrome (hereditary nonpolyposis colorectal cancer) who were predisposed to develop colon cancer showed no effect of long-term intake of resistant starch on cancer development. 222 In that study, however, the dose of starch and, thus, the amount of available SCFAs were much lower than in the trial by Le Leu et al. 218 Furthermore, the development of hereditary colorectal cancer might involve mechanisms other than those targeted by SCFAs. Le Leu et al 218 also used a highly toxigenic diet in which the butyrylated starch counteracted the toxic effects of, for example, red meat, while the Lynch patients consumed a normal diet. It is possible that some markers might show changes at an early stage of colon cancer, eg, the proliferation markers used by Le Leu et al, 218 while other markers show changes at a later stage of colon cancer development, such as those used in the Lynch study. In conclusion, these 2 studies do not provide a definitive answer.
Although the role of dietary fiber in relation to colorectal cancer has been investigated for many years, recent original studies continue to provide new insights. O'Keefe et al 223 conducted a 2-week dietary intervention trial in native Africans, who have a low rate of colorectal cancer, and African Americans, who have a 10-fold higher rate of colorectal cancer. Native African participants switched from their traditional high-fiber diets to low-fiber Western diets, and the American participants switched to the fiber-rich diet. The dietary changes affected the gut microbiome and led to profound changes in metabolites. An increase in saccharolytic fermentation and butyrogenesis as well as suppression of secondary bile acid synthesis was observed in African American participants after switching to a high-fiber, low-fat diet. These changes were associated with a significant reduction in both colonic mucosal inflammation and proliferation biomarkers of cancer risk. In sharp contrast, the diet switch for 2 weeks to a high-fat, low-fiber diet in rural African participants resulted in reverse changes in all these parameters. 223 It must be noted however, that these findings need to be confirmed in longitudinal studies, as there is still controversy over the effects of dietary fiber on colorectal cancer. Indeed, a large pooled analysis of data from 13 prospective cohort studies failed to show a linear inverse association between dietary fiber intake and risk of colorectal cancer. 224 Clearly, the amount of dietary fiber consumed per day may influence outcome. Rather high doses of more than 50 g/d (as in the study of O'Keefe et al 223 ), as well as a microbiome that is able to generate sufficient amounts of butyrate, 139 may be needed to observe a protective effect against colorectal cancer. In addition, dietary interactions may play a role. For example, it was recently shown that a vegetarian diet, in particular a pesco-vegetarian diet, was associated with a lower risk of colorectal cancer. 225 Potential underlying mechanisms of such dietary interactions have been recently reviewed. 226 Prodrugs offer the possibility to treat already developed tumorous tissue. Since trials of these medications are under strict rules and are limited to severely diseased populations, not many have been conducted. In several human clinical trials on prodrugs in patients with various types of cancers, including colon cancer, prostate cancer, non-small cell lung cancer, and resistant myeloid neoplasm, only limited improvement or stabilization of disease was described. [227] [228] [229] [230] [231] [232] [233] A limitation of these phase I pharmacological studies is that they are primarily designed to evaluate the toxicity and maximum or optimal dose of the prodrug. For ethical reasons, only certain tumors refractory to standard therapy were investigated, and prodrug therapy was not targeted at colon cancer specifically. The field of prodrug treatment is still developing, so studies targeted specifically at colon cancer might be conducted in the future.
CLINICAL HUMAN INTERVENTION TRIALS: MUCOSAL HEALING AND THE INTESTINAL BARRIER
Prior to major colonic surgery, the bowel is cleansed of feces to avoid anastomotic leaks and secondary infections by bacterial content. However, several studies have shown that bowel preparation does not contribute to better anastomotic healing or the prevention of anastomotic leakage. [234] [235] [236] This lack of effect might be attributable to lower SCFA levels in the cleansed colon. As far as can be determined, however, no human studies have been conducted to assess the effects of SCFAs on mucosal healing. Several studies have, however, attempted to improve the protective characteristic of the intestinal barrier. In healthy volunteers, an improved intestinal barrier was observed after chronic intake of inulin, a prebiotic known to increase colonic SCFA concentrations. 237 Mucus secretion, however, as measured by the amount of mucins present in 24-hour feces, and MUC2 expression did not differ after rectal butyrate infusions in ulcerative colitis patients in remission compared with placebo or with butyrate treatment in healthy volunteers. 238 Hamer et al 239 reported that butyrate enemas increased the antioxidant status in human healthy volunteers. In ulcerative colitis patients, however, the same authors found no effect on antioxidant status. 67 Some intervention studies have tried to gain insight into cell proliferation rates after SCFA application in humans, showing that mucosal cell proliferation and mucosal blood flow is enhanced after SCFA application in a closed Hartmann's rectum. 37, 240 These studies, however, are translational and do not give direct insight into the possible role of SCFAs in mucosal healing.
FUTURE PERSPECTIVES
Overall, clinical trials on SCFA application have not confirmed the promise of preclinical trials. The higher doses of SCFAs used in animal studies might explain the lack of effect in humans. Another factor, as already noted, is that patients investigated in clinical trials might be refractory to established medication and thereby have far more complicated disease than can be mimicked in animal models. Clinical research is further complicated by the fact that each individual has a specific microbiota composition. This review underlines the importance of expanding research into human investigational studies.
In clinical practice, the colonic application of SCFAs is not yet an established treatment option for colonic disease in humans. Especially in inflammatory bowel disease, the results from human intervention studies are disappointing. The limited effects of SCFA application in inflammatory bowel disease are in line with a recent meta-analysis showing no effect of fiber intake on inflammation. 241 However, the possibility to combine SCFAs with anti-inflammatory drugs such as mesalazine seems promising. 194 In addition, the combination of SCFAs with probiotics or prebiotics, 110 or even the combination of butyrate with a prebiotic plus mesalazine, 242 might have a role in further optimizing the treatment of inflammatory bowel disease. As for the prevention of colon cancer, larger, prospective studies on the use of butyrylated fibers could be conducted to validate the promising effects found in animal studies. Likewise, such studies should be performed to investigate the use of location-specific SCFA prodrugs in the treatment of colon cancer. Animal studies on anastomotic healing are promising, so the application of SCFAs in humans undergoing colonic surgery is another area that warrants research. In the future, butyrate-coated sutures might aid mucosal healing after colonic surgery, as hypothesized from a study that showed better tendon healing when butyric acidimpregnated sutures were used in rats. 243 
CONCLUSION
The use of SCFAs, especially butyrate but also acetate and propionate, to treat colonic diseases has shown promising results in vitro and ex vivo. When viewing data from current research, however, it does not seem likely that SCFA treatment as a stand-alone therapy will prove effective in treating or preventing colonic diseases. In the future, the use of SCFAs combined with anti-inflammatory drugs, prebiotics, or probiotics, the use of prodrugs in the case of carcinogenesis, or the direct application of SCFAs using SCFA-coated accessories to improve mucosal healing after colonic surgery may provide new therapeutic options.
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